CRB opens second office in Europe, hires Bernd Müller

Friday, October 5, 2018 @ 2:00 pm

CRB Group GmbH, one of Europe’s leading providers of design and consulting solutions for the global life science marketplace, has announced the opening of a second office in Europe. The new office, located in Stuttgart, supports the growing need for experts in project execution to support the pharmaceutical and biotechnology industry in the region.

“The opening of operations for CRB in Germany strategically aligns with our clients’ growth in the region over the last decade and allows us to serve their needs locally,” CRB president, Ryan Schroeder, said. “In addition, Germany’s commitment to research and manufacturing in the life science industry makes it a natural fit for the expertise of our team.”

CRB has hired Bernd Müller as the project team leader in the Stuttgart office. Müller has more than 20 years of experience in the industry, managing teams on major projects for European companies, including Octapharma, CSL Behring, Roche Diagnostics, Boehringer Ingelheim and more.

“The addition of Bernd in Stuttgart to our European network is key to our continued growth in the region,” Eric Unrau, CRB’s regional leader for Europe, said. “Whether it’s a small research study or a complex construction project, we will be able to better serve our clients by having a team that is “on the ground.””

CRB’s offices in Basel, Switzerland and Stuttgart, Germany will continue to focus on life science projects in Europe.

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

SOTIO enters into agreement with Biocytogen to expand antibody-drug conjugates pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million
July 16, 2024

Asceneuron secures USD 100 million financing to advance therapeutics in neurodegenerative diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical developme
July 16, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Newron flash update “A pivotal year” - potential of schizophrenia drug

June 27, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024